Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering and Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, Montreal, Québec, Canada.
PLoS One. 2013;8(3):e58394. doi: 10.1371/journal.pone.0058394. Epub 2013 Mar 12.
The beneficial effect of a microencapsulated feruloyl esterase producing Lactobacillus fermentum ATCC 11976 formulation for use in non-alcoholic fatty liver disease (NAFLD) was investigated. For which Bio F1B Golden Syrian hamsters were fed a methionine deficient/choline devoid diet to induce non-alcoholic fatty liver disease. Results, for the first time, show significant clinical benefits in experimental animals. Examination of lipids show that concentrations of hepatic free cholesterol, esterified cholesterol, triglycerides and phospholipids were significantly lowered in treated animals. In addition, serum total cholesterol, triglycerides, uric acid and insulin resistance were found to decrease in treated animals. Liver histology evaluations showed reduced fat deposits. Western blot analysis shows significant differences in expression levels of key liver enzymes in treated animals. In conclusion, these findings suggest the excellent potential of using an oral probiotic formulation to ameliorate NAFLD.
研究了微囊化阿魏酸酯酶产生的德氏乳杆菌 ATCC 11976 配方对非酒精性脂肪性肝病（NAFLD）的有益作用。为此，用蛋氨酸缺乏/胆碱缺乏饮食喂养 Bio F1B 金黄叙利亚仓鼠以诱导非酒精性脂肪性肝病。结果首次显示实验动物的显著临床益处。脂质检查表明，治疗组动物肝内游离胆固醇、酯化胆固醇、甘油三酯和磷脂浓度显著降低。此外，治疗组动物血清总胆固醇、甘油三酯、尿酸和胰岛素抵抗降低。肝组织学评估显示脂肪沉积减少。Western blot 分析显示治疗组动物关键肝酶的表达水平存在显著差异。总之，这些发现表明使用口服益生菌制剂改善 NAFLD 的潜力巨大。
